Spyre Therapeutics, Inc. (SYRE)
NASDAQ: SYRE · Real-Time Price · USD
33.45
-0.06 (-0.18%)
Dec 5, 2025, 4:00 PM EST - Market closed
Spyre Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
65
Market Cap
2.60B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
SYRE News
- 20 hours ago - Spyre Therapeutics Announces Grants of Inducement Awards - GlobeNewsWire
- 4 weeks ago - Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody - GlobeNewsWire
- 6 weeks ago - Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 - GlobeNewsWire
- 7 weeks ago - Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - GlobeNewsWire
- 7 weeks ago - Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewsWire
- 7 weeks ago - Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 2 months ago - Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - GlobeNewsWire